Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase in Relapse After Allogeneic Stem Cell Transplantation
Patients will received Imatinib at a dose of 400mg daily. The tolerability of Imatinib given
at a daily dose of 400mg will be assessed. The hematologic, cytogenetic and molecular
responses will be evaluated at various check points.
Donor/recipient chimerism during Imatinib therapy will be assessed. Survival will be
estimated.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
- to assess the tolerability of Imatinib given at a daily dose of 400mg
François GUILHOT, MD
Study Chair
Department of Oncology Hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
020947
NCT00219726
May 2002
July 2007
Name | Location |
---|